<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38340741</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>403</Volume><Issue>10429</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>02</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Viral gastroenteritis.</ArticleTitle><Pagination><StartPage>862</StartPage><EndPage>876</EndPage><MedlinePgn>862-876</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(23)02037-8</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(23)02037-8</ELocationID><Abstract><AbstractText>Since the discovery of norovirus in 1972 as a cause of what was contemporarily known as acute infectious non-bacterial gastroenteritis, scientific understanding of the viral gastroenteritides has continued to evolve. It is now recognised that a small number of viruses are the predominant cause of acute gastroenteritis worldwide, in both high-income and low-income settings. Although treatment is still largely restricted to the replacement of fluid and electrolytes, improved diagnostics have allowed attribution of illness, enabling both targeted treatment of individual patients and prioritisation of interventions for populations worldwide. Questions remain regarding specific genetic and immunological factors underlying host susceptibility, and the optimal clinical management of patients who are susceptible to severe or prolonged manifestations of disease. Meanwhile, the worldwide implementation of rotavirus vaccines has led to substantial reductions in morbidity and mortality, and spurred interest in vaccine development to diminish the impact of the most prevalent viruses that are implicated in this syndrome.</AbstractText><CopyrightInformation>Copyright © 2024 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Flynn</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olortegui</LastName><ForeName>Maribel Paredes</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Unidad de Investigaciones Biomédicas, Asociación Benéfica PRISMA, Iquitos, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosek</LastName><ForeName>Margaret N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA. Electronic address: mnk2n@virginia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>D43 TW010913</GrantID><Acronym>TW</Acronym><Agency>FIC NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AI055432</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005759" MajorTopicYN="Y">Gastroenteritis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007182" MajorTopicYN="N">Income</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029322" MajorTopicYN="Y">Norovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019651" MajorTopicYN="Y">Plastic Surgery Procedures</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of interests TGF was supported by the Global Biothreats Training Program (NIH T32 AI055432) and the Division of Infectious Diseases and International Health Fellowship Program at the University of Virginia (Charlottesville, VA, USA). MNK and MPO were supported by the Fogarty International Center at the US National Institutes of Health (D43TW010913). Funding sources had no role in the writing of this Seminar.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>11</Day><Hour>7</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>10</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38340741</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(23)02037-8</ArticleId><ArticleId IdType="pii">S0140-6736(23)02037-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle>